IDEV Technologies Completes US$46 Million Preferred Stock Financing With Piper Jaffray and Additional Strategic Investor

Proceeds to Fund Clinical Trials, New Product Development, Continued Revenue Growth

WEBSTER, Texas, October 7, 2010 - IDEV Technologies, Incorporated (IDEV), an emerging leader in the
development and commercialization of minimally invasive medical technologies,
today announced that it has completed a US$46 million Series D round of
financing, with Piper Jaffray & Co.'s Merchant Banking Fund (PJC Capital LLC)
and a leading strategic global healthcare company as the two new investors.
The financing also included strong support and additional investment from
existing venture capital firms PTV Sciences, Bay City Capital, RiverVest
Venture Partners and Heron Capital.

The proceeds from the financing will be used to fund SUPERB, the ongoing,
multi-center IDE superficial femoral artery clinical trial for the company's
self-expanding SUPERA(R) stent, new clinical trials in support of other
peripheral artery indications, the development of new interventional
products, and sales and marketing initiatives to support continued revenue
growth. IDEV continues to achieve success from the recent European launch of
its SUPERA VERITAS(TM) Peripheral Vascular System, an easy to use, reliable
and precise stent delivery system developed to deliver the SUPERA stent. In
addition, the company is pleased with the positive market reaction to the
initial data released from a European registry which yielded promising
results in the superficial femoral (SFA) and popliteal arteries. The company
is very encouraged by these preliminary data and believes it demonstrates the
durability of the innovative self-expanding SUPERA stent.

Christopher M. Owens, President and CEO of IDEV, said, "We have strong
support from our existing investors and we are excited to be working with our
two new corporate partners, Piper Jaffray, a leading international investment
bank and institutional securities firm with significant experience in the
medical technology sector and the additional new investor, a leading
strategic global healthcare company. We appreciate the enthusiastic interest
and financial support of both existing and new investors. This is an exciting
time for IDEV. In addition to the completed financing and the successful
European launch of VERITAS, we are seeing significant progress on our key
initiatives such as the enrollment of our SUPERB superficial femoral artery
IDE trial for the SUPERA stent and for the new product launches scheduled for
this year. Furthermore, I am pleased that we continue to achieve accelerated
revenue growth while building a strong foundation for the future."

Proceeds from the financing will advance IDEV's strategy of creating a
world-class interventional platform to address the unmet clinical needs of
the nearly 120 million patients who suffer from peripheral artery disease.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in the interventional radiology,
vascular surgery and cardiology marketplace. IDEV's worldwide headquarters is
located in Webster, Texas and its European headquarters is located in
Beuningen, The Netherlands. Please visit www.idevmd.com.

The SUPERA stent is currently indicated in the US for the palliative
treatment of biliary strictures produced by malignant neoplasms and in Europe
for both the treatments of biliary strictures produced by malignant neoplasms
and for peripheral vascular use following failed percutaneous transluminal
angioplasty (PTA).

    Contact: William W. Burke
             Executive Vice President & Chief
             Financial Officer
             IDEV Technologies, Incorporated
             +1-281-525-2000

             Donna Lucchesi
             Vice President Global Marketing
             IDEV Technologies, Incorporated
             +1-281-525-2000

William W. Burke, Executive Vice President & Chief Financial Officer, or Donna Lucchesi, Vice President Global Marketing, both of IDEV Technologies, Incorporated, +1-281-525-2000